PDT Partners’s Aprea Therapeutics APRE Stock Holding History

PDT Partners’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,472	Closed	-$55K	–	946
2022 Q1	$55K	Sell	1,472 -5,658	-79%	-$232K	﹤0.01%	903
2021 Q4	$409K	Buy	7,130 +2,743	+63%	+$242K	0.03%	585
2021 Q3	$448K	Sell	4,387 -1,825	-29%	-$166K	0.03%	499
2021 Q2	$606K	Buy	+6,212	New	+$574K	0.04%	475

Other funds holding APRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

PDT Partners's APRE Position: Q2 2022 in Review

PDT Partners sold out of Aprea Therapeutics (APRE) in Q2 2022, closing a stake of 1,472 shares — an estimated $55K sold.

PDT Partners first reported a position in APRE in Q2 2021 and held it in 4 quarters. The position peaked at $606K in Q2 2021. 33 funds tracked by Wall St. Rank hold APRE as of Q2 2022.

PDT Partners reported no remaining Aprea Therapeutics position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 1,472 Aprea Therapeutics shares in Q2 2022, an estimated $55K.
PDT Partners first reported a position in Aprea Therapeutics in Q2 2021 and held it in 4 quarters.
PDT Partners's Aprea Therapeutics position peaked at $606K in Q2 2021.
33 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.